30 Aug Third Wave and 3M couple biotech technologies
MADISON, Wis.—Third Wave Technologies and 3M announced Wednesday the signing of a supply agreement that will provide Third Wave customers with the option of coupling its Invader technology, a DNA and RNA analysis chemistry, with 3M’s microfluidic technology.
Under the agreement, 3M Bioanalytical Technologies Project will supply Third Wave with its microfluidic technology. This new platform option is intended to allow clinical laboratories to forgo the numerous liquid-handling steps, shortening the time to test results.
“We’re excited to combine 3M’s innovative microfluidic technology with Third Wave’s Invader chemistry to provide customers with an exciting diagnostic platform,” said Gregg Vandesteeg, staff vice president, research anddevelopment, 3M Health Care Business. “Our microfluidic platform and Third Wave’s Invader products are ideal complements.”
“Third Wave is very pleased to partner with 3M, a world leader in health care innovation, to offer an exceptional platform option to our customers,” said John Puisis, president and chief executive officer of Third Wave. “Our agreement with 3M will enable us to provide an innovative, valuable solution that responds to our customers’ desire for even simpler and easier-to-use molecular diagnostic products.”
Madison-based Third Wave Technologies is a provider and developer of molecular diagnostics for a variety of DNA and RNA analysis applications.